Biogen Idec Trading Higher on ISI Group Upgrade

Biogen Idec

is trading over 4% higher after ISI Group group upgraded the company to Buy. The shares of BIIB are currently trading at $99.06. Biogen Idec Inc., a biotechnology company, discovers, develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally.